Related Experiment Videos
Reversible thrombocytopenia with levamisole
1Department of Medicine, University of Toronto, Ontario, Canada.
Medical and Pediatric Oncology
|April 1, 1995
Summary
Levamisole can cause a rare but serious side effect called thrombocytopenia, a low platelet count. This case highlights the importance of considering levamisole-induced thrombocytopenia in patients receiving this drug for cancer treatment.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Levamisole is an immunomodulatory drug used in adjuvant cancer therapy.
- Agranulocytosis is a known hematologic side effect of levamisole.
- Adjuvant therapy with levamisole is increasingly used for melanoma and colon cancer.
Observation:
- A patient developed thrombocytopenia (low platelet count) almost two years after initiating adjuvant levamisole for malignant melanoma.
- The thrombocytopenia was confirmed to be related to levamisole through drug rechallenge.
Findings:
- Levamisole-induced thrombocytopenia (LIT) is a rare hematologic adverse event.
- This case demonstrates a delayed onset of LIT in a patient treated for malignant melanoma.
Implications:
- Clinicians should be vigilant for levamisole-induced thrombocytopenia, even with prolonged treatment.
- Increased recognition of LIT may be necessary as levamisole use expands in adjuvant cancer therapy.
- Prompt diagnosis and management of LIT are crucial for patient safety in oncology settings.